Introduction {#s0001}
============

Purple acid phosphatase (PAP; E.C.3.1.3.2) is a binuclear hydrolase that has been isolated from various mammals and plants[@CIT0001]. Mammalian PAP is also known as tartrate-resistant acid phosphatase[@CIT0002] or osteoclastic acid phosphatase[@CIT0003]. These enzymes are distinguished from other acid phosphatases by their characteristic purple color in concentrated solution[@CIT0004]. PAPs catalyze the hydrolysis of phosphorylated substrates under neutral to acidic conditions *in vivo*[@CIT0001]. Several crystal structures of PAPs have been described, including those from plants (red kidney bean and a sweet potato PAP) as well as from mammals (pig, human and rat)[@CIT0005] and references 90--93 therein. The enzyme structures from the two plant organisms are homodimers consisting of 55 kDa subunits, while the mammalian PAPs are 35 kDa monomers[@CIT0006]. Despite the apparent difference between the structures of plant and animal PAPs, and the low degree of overall amino acid sequence homology between enzymes from different kingdoms, their catalytic sites display a remarkable similarity[@CIT0005] and references 2, 89, 107 therein ([Figure 1](#F0001){ref-type="fig"}) and include two metal centers, which are coordinated by seven invariant ligands (one aspartate, one tyrosine and one histidine for Fe^3+ ^and two histidines and one asparagine for Zn^2+^), with an aspartate residue bridging the two ions[@CIT0010]. Due to the structural similarity in their catalytically relevant active sites, all PAPs are believed to employ highly conserved mechanistic strategies[@CIT0001].

![(Left) Active site of all known PAPs has an Fe^3+ ^in the active site, which coordinates with an invariant tyrosine ligand, producing a ligand to metal CT transition giving rise to the characteristic purple color of the enzyme. PAPs active site also contains a divalent metal ion which may be either Zn^2+^, Mn^2+ ^or Fe^2+^. The seven metal ion-coordinating residues are invariant among PAPs from different sources. Residue labels refer to the sequences of red kidney bean PAP and pig PAP (in brackets or parentheses). Taken from Schenk et al.[@CIT0005] (Right) SDS--PAGE illustrates PAP purity (lane 1). M, molecular size markers.](IENZ_A_1230109_F0001_C){#F0001}

The biological roles of PAPs are diverse and depend on the host organism. Plant PAPs are believed to assist in mobilizing organic phosphate esters in soil during germination[@CIT0011], and mammalian PAPs have been linked with iron transport during pregnancy[@CIT0012]. Both may be involved in bacterial killing since they are able, at least *in vitro*, to generate reactive oxygen species via Fenton chemistry as a response against pathogens[@CIT0009]^,^[@CIT0013]^,^[@CIT0014]. The association of mammalian PAP activity with osteoporosis[@CIT0002]^,^[@CIT0015] has prompted investigators, around the world, to examine its potential as a therapeutic target for the treatment of this disease, and to develop potent inhibitors of this enzyme[@CIT0017]^,^[@CIT0018]. It is known that PAP is secreted into the bone-resorptive space in mammals[@CIT0002], and PAP activity has long been associated with bone resorption[@CIT0019]. In addition, transgenic mice in which the PAP enzyme was over-expressed developed osteoporosis due to increased bone resorption[@CIT0020], whereas the corresponding knockout mice exhibited the opposite condition (osteopetrosis), further implicating the role of PAP in this process[@CIT0004], and establishing PAP as a drug target in the treatment of osteoporosis[@CIT0021]. Although clinical treatments are available for osteoporosis, notably bisphophonates, which inhibit farnesylpyrophosphate synthase in osteoclast[@CIT0022], but these drugs have significant side effects and compliance issues. Also, a number of PAPs inhibitors including fluoride[@CIT0023], and several tetrahedral inorganic oxyanions, including phosphate, arsenate, vanadate, tungstate and molybdate[@CIT0007]^,^[@CIT0024] have been discovered, but most of these do not possess drug-like properties and so are not suitable for further modifications that may convert them into chemotherapeutic agents. Myers et al.[@CIT0025] have described a number of simple phosphonates with pendant metal-binding groups, such as thiol, phosphonate and carboxylate, and these have shown inhibitory activity against red kidney PAP (rkbPAP), in the range 80--3000 µM. Moreover, several modified phosphotyrosine containing tripeptides have also shown inhibitory activity toward several mammalian and plant PAPs, with IC~50~ values in the mid-micromolar range[@CIT0021]. More recently, α-alkoxynaphthylmethylphosphonic acids and acyl derivatives of α-aminonaphthylmethylphosphonic acid have also been shown to be PAP inhibitors with *K*~i~ and IC~50~ values in the low micromolar range[@CIT0018]^,^[@CIT0026]. These molecules were designed as the derivatives of 1-naphthylmethylphosphonic acid, a PAP inhibitor previously reported by Schwender et al.[@CIT0003] A number of phosphonate- and carboxylate-containing derivatives of these substrates have been synthesized, and these displayed mid- to low-micromolar inhibitory potency against several mammalian and plant PAPs[@CIT0021].

The current study is particularly novel and significant because to the best of our knowledge, no previous similar studies have been reported on possible inhibitory potential of diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives on the PAP enzyme. Based on previous lead compound(s) and rational drug design, different sulfonyl derivatives of alkylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid with varying lengths of alkyl chains were synthesized and evaluated as PAP inhibitors. The sulfonyl and alkyl groups were introduced for two reasons: (i) the sulfonyl group was expected to improve the water solubility of these compounds; (ii) McGeary et al. have previously reported that PAP inhibitors bearing an alkoxy group with long alkyl chain were superior to those that did not, suggesting effective hydrophobic interactions between the alkyl group of the inhibitors and nonpolar surface residue near the enzyme's active site[@CIT0018]; (iii) a nonclassical bioisosteric replacement was made in which the acyl moiety was changed to sulfonamide one. Therefore, inhibitors of general structures in [Scheme 1](#SCH0001){ref-type="scheme"} with C~6~, C~8~, C~12~ and C~16~ alkyl chains were examined. Moreover, to evaluation of coordination of phosphonate moiety to the bimetal center, the ethyl groups were attached to the oxygen atoms of phosphonate. The aim of the current study was also to expand this working framework through suggesting a molecular modeling component to advance the mechanistic understanding of PAP--drug interactions.

![Synthesis of diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives.](IENZ_A_1230109_SCH0001_B){#SCH0001}

Materials and methods {#s0002}
=====================

Chemistry {#s0003}
---------

All starting materials, reagents, and solvents were purchased from Merck Finnigan (Germany). The purity of the synthesized compounds was confirmed by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 F254 plates were applied for analytical TLC. Column chromatography was performed on Merck silica gel (70--230 mesh) for purification of the intermediate and final compounds. Melting points were determined on a Kofler hot stage apparatus (Vienna, Austria) and are uncorrected. ^1^H NMR spectra were recorded using a Bruker 500 spectrometer (Bruker, Rheinstatten, Germany), and chemical shifts are expressed as *δ* (ppm) with tetramethylsilane (TMS) as an internal standard. Coupling constants (*J*) are reported in hertz and peak multiplicities described as singlet (s), doublet (d), triplet (t), multiplet (m) or broad (br). The IR spectra were obtained on a Shimadzu 470 (Shimadzu, Tokyo, Japan) spectrophotometer (potassium bromide disks). The mass spectra were run on a Finnigan TSQ-70 spectrometer (Finnigan) at 70 eV.

General procedure for the syntheses and spectral data of the synthesized compounds {#s0004}
----------------------------------------------------------------------------------

### General procedure for the synthesis of diethyl(amino(4-methoxyphenyl)methyl)phosphonate (2) {#s0005}

This compound was prepared according to the general procedure described in the literature[@CIT0003]^,^[@CIT0018]^,^[@CIT0026]^,^[@CIT0027]. NH~4~OAc (7.70 g, 0.10 mol) was added to EtOH (20 mL) in the round-bottomed flask containing the activated molecular sieves, followed by the addition of *p*-methoxybenzaldehyde (**1**) (13.60 mL, 0.10 mol) and diethyl phosphite (12.90 mL, 0.10 mol). The reaction mixture was stirred at 60 °C under nitrogen atmosphere for 48 h. Once it has cooled to room temperature, conc. HCl was added to the resulting mixture to acidify it to pH 1, and then was washed with Et~2~O (50 mL). Addition of 2 M NaOH to the aqueous layer changed the pH to 11, and the product was extracted with dichloromethane (100 mL) to give the free base of diethyl (amino(naphthalen-1-yl)methyl)phosphonate[@CIT0027] as yellow oil. The product was later treated with HCl gas in EtOH (10 mL)--Et~2~O (10 mL). Et~2~O (20 mL) was further added to the resulting solution, and the solvent was evaporated to obtain the hydrochloride salt of diethyl compound **2** as white solid.

### General procedure for the preparation of diethyl (alkylamido(4-methoxyphenyl)methyl)phosphonates (3a--3d) {#s0006}

This compound was prepared according to the general procedure described in the literature[@CIT0027]. A solution of DIPEA (2.60 mL, 15.2 mmol) and the hydrochloride salt **2** (0.50 g, 1.52 mmol) in CH~2~Cl~2~ (5 mL) were then added dropwise to the sulfonyl chloride and the reaction mixture was stirred under argon N~2~ for 24 h. The crude product was purified using silica flash column chromatography (10--60% EtOAc in light petroleum) to give **3a**--**3h**.

### General procedure for the preparation of (alkylamido(4-methoxyphenyl)methyl)phosphonic acids (4a--4d) {#s0007}

This compound was prepared according to the general procedure described in the literature[@CIT0027]. NaI (5 equiv) and distilled MeCN (5 mL) were added to the corresponding diethyl ester **3a**--**3d** (1 equiv). Distilled TMSCl (5 equiv) was then added to the mixture, which was then stirred at 40 °C under N~2~ for 18 h. MeCN was removed *in vacuo.* The precipitate was then extracted with EtOAc (3 × 10 mL), washed with NaS~2~O~3~ (10 mL), water and NaCl (2 × 10 mL), followed by drying with NaSO~4~. The product was then co-evaporated with toluene (3 × 5 mL), and purified under high vacuum to give the corresponding phosphonic acids **4a**--**4d**.

### Diethyl(amino(4-methoxyphenyl)methyl)phosphonate (2) {#s0008}

*Molecular weight*: 204 (g/mol), FT-IR (KBr, cm^−1^): 3429 (stretch NH), 2935 (stretch CH, aromatic), 2904 (stretch CH, aliphatic), 1608 (stretch C=C, aromatic), 1519 (bending NH), 1462 (bending CH~2~), 1388 (bending CH~3~), 1242 (stretch C--O), 1026 (stretch C--O, OCH~3~), 948 (stretch CH, oop), 547 (bending NH).

### Diethyl(hexylsulfonamido(4-methoxyphenyl)methyl)phosphonate (3a) {#s0009}

*Molecular weight*: 421 (g/mol), FT-IR (KBr, cm^−1^): 3437 (stretch NH), 2931 (stretch CH, aromatic), 2873 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1516 (bending NH), 1465 (bending CH~2~), 1392 (bending CH~3~), 1311, 1188 (stretch O=S=O), 1249 (stretch C--O), 1041 (stretch C--O, OCH~3~), 952 (stretch CH, oop), 551 (bending NH).

^1^H NMR (CDCl~3~, 300 MHz): *δ* (ppm): 7.68--7.66 (d, *J* = 6 Hz, 1H, N**H**), 7.39--7.36 (dd, *J* = 1.5, 1.5 Hz, 2H, C~(2,6)~**H** aromatic), 6.80--6.78 (d, *J* = 6.6 Hz, 2H, C~(3,5)~**H** aromatic), 5.52--5.44 (dd, *J* = 7.2, 7.2 Hz, H, C**H**--P), 4.15--4.04 (m, 2H, C~(1,1\*)~**H**--OP), 3.88--3.79 (m, 1H, C~(1)~**H**--OP), 3.72 (s, 3H, C**H~3~**--O), (m, 1H, C~(1\*)~**H**--OP), 2.16 (t, *J* = 5.7 Hz, 2H, C**H~2~**--S), 1.53 (t, *J* = 5.4 Hz, 2H, C**H~2~**--CH~2~S), 1.28 (t, *J* = 5.4 Hz, 3H, C~(2)~**H~3~**--CH~2~O), 1.15 (bro, *J* = 7.5 Hz, 10H, C**H** aliphatic), 1.03 (t, *J* = 5.7 Hz, 3H, C~(2\*)~**H~3~**--CH~2~O), 0.80 (t, *J* = 5.4 Hz, 3H, C**H~3~**--RS).

### Diethyl((4-methoxyphenyl)(octylsulfonamido)methyl)phosphonate (3b) {#s0010}

*Molecular weight*: 449 (g/mol), FT-IR (KBr, cm^−1^): 3437 (stretch NH), 2927 (stretch CH, aromatic), 2858 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1512 (bending NH), 1465 (bending CH~2~), 1396 (bending CH~3~), 1303, 1215 (stretch O=S=O), 1246 (stretch C--O), 1037(stretch C--O, OCH~3~), 948(stretch CH, oop), 721 (rocking CH~2~), 551 (bending NH).

^1^H NMR (CDCl~3~, 300 MHz): *δ* (ppm): 7.54--7.49 (dd, *J* = 3.6, 3.6 Hz, 1H, N**H**), 7.39--7.35 (dd, *J* = 2.1, 2.1 Hz, 2H, C~(2,6)~**H** aromatic), 6.81--6.78 (dd, *J* = 9 Hz, 2H, C~(3,5)~**H** aromatic), 5.53--5.46 (dd, *J* = 20.7 Hz, H, C**H**--P), 4.14--4.04 (m, 2H, C~(1,1\*)~**H**--OP), 3.88--3.80 (m, 1H, C~(1)~**H**--OP), 3.73 (s, 3H, C**H~3~**--O), 3.68--3.59 (m, 1H, C~(1\*)~**H**--OP), 2.17 (t, *J* = 7.8 Hz, 2H, C**H~2~**--S), 1.54 (t, *J* = 6.9 Hz, 2H, C**H~2~**--CH~2~S), 1.28 (t, *J* = 7.2 Hz, 3H, C~(2)~**H~3~**--CH~2~O), 1.16 (bro, *J* = 7.5 Hz, 10H, C**H** aliphatic), 1.04 (t, *J* = 7.2 Hz, 3H, C~(2\*)~**H~3~**-CH~2~O), 0.81 (t, *J* = 6.9 Hz, 3H, C**H~3~**--RS).

^13^C NMR (CDCl~3~, 75 MHz): *δ* (ppm): 13.9 (CH3--RS), 16.1 (C~(2\*)~H3 ethoxy), 16.3 (C~(2)~H3 ethoxy), 22.5 & 22.6 & 29.1 & 29.2 & 31.7 & 36.1 (CH~2~ alkyl), 48.1(C~(1\*)~H~2~ ethoxy), 49.7 (C~(1)~H~2~ ethoxy), 55.0 (P--CH--N), 62.8 (S--CH~2~), 63.1 (CH~3~ methoxy), 113.7 (C~3,5~ phenyl), 127.3 (C~2,6~ phenyl), 129.4 (C~1~ phenyl), 159.2 (C~4~ phenyl).

### Diethyl(dodecylsulfonamido(4-methoxyphenyl)methyl)phosphonate (3c) {#s0011}

*Molecular weight*: 505 (g/mol), FT-IR (KBr, cm^−1^): 3444 (stretch NH), 2924 (stretch CH, aromatic), 2854 (stretch CH, aliphatic), 1651 (stretch C=C, aromatic), 1512 (bending NH), 1458 (bending CH~2~), 1396 (bending CH~3~), 1311, 1176 (stretch O=S=O), 1211(stretch C--O), 1041 (stretch C--O, OCH~3~), 948 (stretch CH, oop), 729 (rocking CH~2~), 547 (bending NH).

^1^H NMR (CDCl~3~, 300 MHz): *δ* (ppm): 7.55--7.53 (dd, *J* = 2.1, 2.1 Hz, 1H, N**H**), 7.38--7.36 (dd, *J* = 1.2 Hz, 2H, C~(2,6)~**H** aromatic), 6.81--6.79 (d, *J* = 5.1 Hz, 2H, C~(3,5)~**H** aromatic), 5.51--5.45 (dd, *J* = 5.7, 5.7 Hz, H, C**H**--P), 4.13--4.07 (m, 2H, C~(1,1\*)~**H**--OP), 3.85--3.82 (m, 1H, C~(1)~**H**--OP), 3.73 (s, 3H, C**H~3~**--O), 3.66--3.61 (m, 1H, C~(1\*)~**H**--OP), 2.17 (t, *J* = 4.2 Hz, 2H, C**H~2~**--S), 1.54 (t, *J* = 6.9 Hz, 2H, C**H~2~**--CH~2~S), 1.28 (t, *J* = 4.2 Hz, 3H, C~(2)~**H~3~**--CH~2~O), 1.16 (bro, *J* = 7.5 Hz, 10H, C**H** aliphatic), 1.04 (t, *J* = 4.2 Hz, 3H, C~(2\*)~**H~3~**--CH~2~O), 0.83 (t, *J* = 6.9 Hz, 3H, C**H~3~**--RS).

^13^C NMR (CDCl~3~, 75 MHz): *δ* (ppm): 13.9 (CH3--RS), 16.1 (C~(2\*)~H3 ethoxy), 16.3 (C~(2)~H3 ethoxy), 22.5 & 22.6 & 29.1 & 29.2 & 29.4 & 31.7 & 36.2 (CH~2~ alkyl), 48.4(C~(1\*)~H~2~ ethoxy), 49.6 (C~(1)~H~2~ ethoxy), 55.1 (P--CH--N), 62.8 (S--CH~2~), 63.1 (CH~3~ methoxy), 113.8 (C~3,5~ phenyl), 127.3 (C~2,6~ phenyl), 129.4 (C~1~ phenyl), 159.2 (C~4~ phenyl).

### Diethyl(hexadecylsulfonamido(4-methoxyphenyl)methyl)phosphonate (3d) {#s0012}

*Molecular weight*: 561 (g/mol), FT-IR (KBr, cm^−1^): 3433 (stretch NH), 2920 (stretch CH, aromatic), 2850 (stretch CH, aliphatic), 1608 (stretch C=C, aromatic), 1512 (bending NH), 1465 (bending CH~2~), 1400 (bending CH~3~), 1307, 1184 (stretch O=S=O), 1249 (stretch C--O), 1053 (stretch C--O, OCH~3~), 968 (stretch CH, oop), 721 (rocking CH~2~), 536 (bending NH).

^1^H NMR (CDCl~3~, 300 MHz): *δ* (ppm): 7.36--7.33 (dd, *J* = 1.5, 1.8 Hz, 2H, C~(2,6)~**H** aromatic), 6.85--6.83 (d, *J* = 6.3 Hz, 2H, C~(3,5)~**H** aromatic), 6.60--6.56 (dd, *J* = 3.3, 3.3 Hz, 1H, N**H**), 5.47--5.40 (dd, *J* = 7.2, 7.2 Hz, H, C**H**--P),4.13--4.07 (m, 2H, C~(1,1\*)~**H**--OP), 3.92--3.86 (m, 1H, C~(1)~**H**--OP), 3.70 (s, 3H, C**H~3~**--O), 3.68--3.64 (m, 1H, C~(1\*)~**H**--OP), 2.19 (t, *J* = 6 Hz, 2H, C**H~2~**--S), 1.58 (t, *J* = 5.7 Hz, 2H, C**H~2~**--CH~2~S), 1.29 (t, *J* = 5.1 Hz, 3H, C~(2)~**H~3~**--CH~2~O), 1.23 (bro, *J* = 7.5 Hz, 26H, C**H** aliphatic), 1.07 (m, *J* = 5.1 Hz, 3H, C~(2\*)~**H~3~**--CH~2~O), 0.85 (t, *J* = 5.4 Hz, 3H, C**H~3~**--RS).

### (Hexylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid (4a) {#s0013}

*Molecular weight*: 365 (g/mol), FT-IR (KBr, cm^−1^): 3433 (stretch NH), 2931 (stretch CH, aromatic), 2866 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1516 (bending NH), 1462 (bending CH~2~), 1392 (bending CH~3~), 1303, 1188 (stretch O=S=O), 1045 (stretch C--O, OCH~3~), 952 (stretch CH, oop), 775 (rocking CH~2~), 559 (bending NH).

^1^H NMR (CH~3~OH-d~4~, 300 MHz): *δ* (ppm): 7.38--7.35 (d, *J* = 8.4 Hz, 2H, C~(2,6)~**H** aromatic), 6.90--6.86 (d, *J* = 4.2 Hz, 2H, C~(3,5)~**H** aromatic), 5.46--5.29 (dd, *J* = 21, 21 Hz, H, C**H**-P), 3.77 (s, 3H, C**H~3~**--O), 2.28 (t, *J* = 7.2 Hz, 2H, C**H~2~**--S), 1.59 (t, *J* = 5.7 Hz, 2H, C**H~2~**--CH~2~S), 1.25 (bro, 6H, C**H** aliphatic), 0.85 (t, *J* = 5.4 Hz, 3H, C**H~3~**--RS).

MS (*m/z*, %): 365 (M), 364 (M-1, 4), 336 (M-29, 1), 310(M-57, 2), 284 (M-81, 9), 216 (M-148, 2), 163 (M-201, 18), 148 (M-216, 11), 136 (M-229, 26), 106 (M-259, 9), 91 (M-274, 13), 83 (M-282, 49), 72 (M-293, 78), 56 (M-311, 76), 43 (M-292, 97).

### ((4-Methoxyphenyl)(octylsulfonamido)methyl)phosphonic acid (4b) {#s0014}

*Molecular weight*: 393 (g/mol), FT-IR (KBr, cm^−1^): 3606 (stretch NH), 2927 (stretch CH, aromatic), 2858 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1516 (bending NH), 1462 (bending CH~2~), 1396 (bending CH~3~), 1307, 1184 (stretch O=S=O), 1041 (stretch C--O, OCH~3~), 960 (stretch CH, oop), 729 (rocking CH~2~), 547 (bending NH).

^1^H NMR (CH~3~OH*-d~4~,* 300 MHz): *δ* (ppm): 7.38--7.36 (dd, *J* = 1.2 Hz, 2H, C~(2,6)~**H** aromatic), 6.9--6.87 (dd, *J* = 6.6 Hz, 2H, C~(3,5)~**H** aromatic), 5.45--5.30 (dd, *J* = 15.9, 5.9 Hz, H, C**H**--P), 3.76 (s, 3H, C**H~3~**--O), 2.29--2.26 (m, 2H, C**H~2~**--S), 1.59 (t, *J* = 5.1 Hz, 2H, C**H~2~**--CH~2~S), 1.25 (bro, 10H, C**H** aliphatic), 0.88 (t, *J* = 2.4 Hz, 3H, C**H~3~**--RS).

MS (*m/z*, %): 393 (M), 321 (M-71, 12), 313 (M-80, 39), 299 (M-94, 17), 204 (M-189, 5), 176 (M-217, 19), 164 (M-229, 18), 148 (M-245, 25), 135 (M-258, 100).

### (Dodecylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid (4c) {#s0015}

*Molecular weight*: 449 (g/mol), FT-IR (KBr, cm^−1^): 3410 (stretch NH), 2920 (stretch CH, aromatic), 2850 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1512 (bending NH), 1462 (bending CH~2~), 1392 (bending CH~3~), 1307, 1184 (stretch O=S=O), 1053 (stretch C--O, OCH~3~), 952 (stretch CH, oop), 725 (rocking CH~2~), 559 (bending NH).

^1^H NMR (CH~3~OH-d~4~, 300 MHz): *δ* (ppm): 7.37--7.36 (dd, *J* = 4.8 Hz, 2H, C~(2,6)~**H** aromatic), 6.88 (t, *J* = 5.1 Hz, 2H, C~(3,5)~**H** aromatic), 5.45--5.31 (dd, *J* = 12.51, 12.57 Hz, H, C**H**--P), 3.76 (s, 3H, C**H~3~**--O), 2.27 (t, *J* = 1.8 Hz, 2H, C**H~2~**--S), 1.58 (t, *J* = 5.7 Hz, 2H, C**H~2~**--CH~2~S), 1.25 (bro, 18H, C**H** aliphatic), 0.88 (t, *J* = 5.4 Hz, 3H, C**H~3~**--RS).

MS (*m/z*, %): 450 (M + 1), 368(M − 81, 25), 281 (M − 169, 12), 233 (M − 217, 17), 218 (M − 232, 13), 163 (M − 286, 33), 148 (M-301, 40), 135 (M − 314, 100).

### (Hexadecylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid (4d) {#s0016}

*Molecular weight*: 505 (g/mol), FT-IR (KBr, cm^−1^): 3603 (stretch OH), 3356 (stretch NH), 2916 (stretch CH, aromatic), 2850 (stretch CH, aliphatic), 1612 (stretch C=C, aromatic), 1512 (bending NH), 1465 (bending CH~2~), 1392 (bending CH~3~), 1311, 1180 (stretch O=S=O), 1037 (stretch C--O, OCH~3~), 952 (stretch CH, oop), 721 (rocking CH~2~), 555 (bending NH).

^1^H NMR (CH~3~OH*-d~4~,* 300 MHz): *δ* (ppm): 7.36--7.34 (d, *J* = 4.8 Hz, 2H, C~(2,6)~**H** aromatic), 6.86--6.84 (d, *J* = 4.8 Hz, 2H, C~(3,5)~**H** aromatic), 3.74 (s, 3H, C**H~3~**--O), 2.27 (s, 2H, C**H~2~**--S), 1.57 (s, 2H, C**H~2~**--CH~2~S), 1.25 (s, Hz, 26H, C**H** aliphatic), 0.86 (t, *J* = 5.4 Hz, 3H, C**H~3~**--RS).

MS (*m/z*, %): 505 (M), 425 (M − 80, 27), 338 (M − 167, 2), 316 (M − 189, 12), 302 (M − 203, 17), 289 (M − 217, 9), 282 (M − 223, 6), 224 (M − 281, 77), 212 (M − 293, 8), 204 (M − 301, 25), 190 (M − 315, 100).

Enzyme preparation and purification {#s0017}
-----------------------------------

PAP from red kidney bean (rkbPAP) was purified following a previously published protocol[@CIT0008]. Briefly, red kidney beans (*Phaseolus vulgaris*), provided from local market, were ground and suspended in 0.5 M sodium chloride solution. The suspension was filtered through a muslin cloth, followed by ethanol fractionation and ammonium sulfate precipitation. The purple enzyme solution was dialyzed against several changes of 0.25 M NaCl over a period of several days. The purple precipitate, which formed in the dialysis bag was collected by centrifugation. The resulting preparation stored at 4 °C in 0.5 M NaCl. The protein identity and purity was tested by SDS--polyacrylamide gel electrophoresis (SDS--PAGE) and by comparing with molecular weight protein markers, by loading the protein samples on a 12% slab gel. Protein concentration was determined by Lowry method[@CIT0028].

Enzyme assay {#s0018}
------------

Inhibition assays for rkbPAP was performed in 96-well multi-titer plates using a microplate reader. Kinetic measurements were taken at pH 4.9 (0.1 M sodium citrate buffer with 5% DMSO) at 25 °C using *p*-nitrophenyl phosphate (*p*-NPP) as the substrate at concentrations of 1, 2, 4, 6, 8, 10, 12, 14, 18 and 24 mM[@CIT0029]. The hydrolysis of *p*-NPP by PAP produces *p*-nitrophenol (*p*-NP), which has a characteristic intense yellow color at 405 nm with *ɛ* = 343 M^−1^ cm^−1^ [@CIT0018]^,^[@CIT0026]. The concentration of enzyme used was ∼60 nM, while at least eight concentrations of each compound ranged from 50 to 2000 µM. The IC~50~ values obtained by "Dose--response inhibition/variable slopes" equation that was performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego CA, [www.graphpad.com](http://www.graphpad.com)). The experimental data are representative example of three independent experiments. In most cases, the standard deviations were almost within 5% of the experimental values, except for some inhibition data points where standard errors of means were within 10% of the measured values. *p* \< .05 was considered statistically significant.

Determination of the inhibition mode and constants {#s0019}
--------------------------------------------------

To determination of inhibition mode, the Michaelis--Menten constant (*K*~m~) and maximum velocity (*V*~max~) and inhibition constants (*K*~i~ and *K*~I~) values were obtained using [Equation (1)](#M0001){ref-type="disp-formula"}[@CIT0029]^,^[@CIT0030] in the presence of at least four concentrations of each compound which were selected from concentration--activity curves. The data were analyzed by nonlinear regression using the program GraphPad Prism $$v = \frac{V_{\max}\left\lbrack S \right\rbrack}{\left\lbrack S \right\rbrack\left( 1 + \left\lbrack I \right\rbrack/K_{I} \right) + K_{m}\left( 1 + \left\lbrack I \right\rbrack/K_{i} \right)}\quad$$ where *K*~i~ and *K*~I~ are the equilibrium dissociation constants for competitive and uncompetitive inhibitor binding, respectively, while, *v*, \[S\] and \[I\] represent the rate of product formation, the substrate and the inhibitor concentration, respectively[@CIT0029]. It has been found that there are two inhibitor constants: *K*~i~, which defined as the dissociation constant of the enzyme--inhibitor complex, and *K*~I~, which defined as the dissociation constant of the enzyme--substrate--inhibitor complex. If *K*~i ~\<~ ~*K*~I~, the type of enzyme inhibition was defined as competitive-noncompetitive and if *K*~i ~\>~ ~*K*~I~, the type of enzyme inhibition was defined as uncompetitive--noncompetitive. The type of enzyme inhibition was defined as pure noncompetitive inhibition when *K*~i ~=~ ~*K*~I~[@CIT0030]. For better visual presentation of data of inhibition mode, the Lineweaver--Burk plots were also provided.

Docking studies {#s0020}
---------------

The structures of molecules were drawn and optimized using HyperChem (HyperCube Inc., Gainesville, FL). Semi-empirical AM1 method with Polak--Ribiere algorithm until the root mean square gradient of 0.01 kcal mol^−1^ was used as the optimization method. The crystal structure of rkbPAP retrieved from the Protein Data Bank (PDB code: 2QFR) was used. Then, after determining Kollman united atom charges[@CIT0033] and merging nonpolar hydrogens, rotatable bonds were assigned. Using autoGrid tool, the grid maps (one for each atom type in the ligand, and one for electrostatic interactions) were constructed adequately large to include the active site of enzyme as well as significant regions of the surrounding surface. In all the cases, a grid map of 60 points in each Cartesian direction besides a grid-point spacing of 0.375 Å (a quarter of the carbon--carbon single bond) were generated. By the ligand location in the complex of ligand--enzyme, the maps were centered on the binding site (Zn atom of the enzyme), searching effective interactions with the functional groups. Based on Lamarckian Genetic Algorithm[@CIT0034], using the pseudo-Solis and Wets local search method[@CIT0035], AutoDock Tools was employed to produce both grid and docking parameter files, that is .gpf and .dpf files. Applying 0.5 Å clustering tolerance to construct clusters of the closest compounds, the initial coordinates of the ligand were used as the reference structure. Finally, docking results (enzyme--inhibitor complex) were visualized using Viewer Lite 4.2.

Results and discussion {#s0021}
======================

Chemistry {#s0022}
---------

The conversion of 4-methoxybenzaldehyde (**1**) into diethyl (amino(4-metoxybenzyl)-methyl)phosphonate was achieved by heating **1** with a mixture of ammonium acetate and diethyl phosphite over activated molecular sieves in ethanol, according to a literature procedure reported for the synthesis of diethyl α-aminobenzylphosphonate from benzaldehyde ([Scheme 1](#SCH0001){ref-type="scheme"})[@CIT0036]. Introducing hydrogen chloride gas to the free amine product gave its corresponding hydrochloride salt **2** in 23% overall yield[@CIT0036]. Alkylation of **2** to give the sulfonamides **3a**--**d** was achieved with adding appropriate sulfonyl chlorides and DIPEA to **2** in chloroform. The reaction mixture was stirred under nitrogen atmosphere for 24 h. The final synthetic step to produce the newly designed inhibitors **4a**--**d** required the cleavage of the phosphonate ester bonds of **3a**--**d** to give their corresponding free phosphonic acids. This was achieved by stirring **3a**--**d** with a mixture of potassium iodide and trimethylsilyl chloride in chloroform at 25 °C for 24 h that giving the desired products in moderate yields.

Enzyme purification and biological activity measurements {#s0023}
--------------------------------------------------------

Although human PAP (hPAP) would be the best choice for our purposes, hPAP can only be obtained in minute quantities using a baculoviral recombinant expression system[@CIT0037]. However, as stated earlier, rkbPAP is a valid model of hPAP (see [Figure 1](#F0001){ref-type="fig"}), as indicated by the highly conserved active sites across these different enzymes, the similarities in substrate binding pockets, and the similarities of inhibition constants for a range of structurally different inhibitors reported for several animal (including human) and plant PAPs[@CIT0018]^,^[@CIT0026]. The rkbPAP was purified from red kidney bean according to the method described by Beck et al.[@CIT0008] The SDS--PAGE analysis is shown in [Figure 1](#F0001){ref-type="fig"}, which clearly indicates the reasonable purity of the isolated PAP. The densitometry of bands indicates that the mass fraction of the purified enzyme is around 0.90 (∼90% purity). It is noteworthy that the plant enzymes are mostly dimeric glycoproteins, and have subunit molecular masses of 50--60 kD. As shown in the figure, differential glycosylation of the subunits, leading to a heterogeneity in the molecular mass of the subunits, has been reported for kidney bean PAP, which is a dimeric glycoprotein (molecular mass 110 kD) with an inter-subunit disulfide linkage[@CIT0011]. Activity staining on PAGE gel also showed that only the ∼50 kDa bands had esterase activity, confirming that there is no contaminant phosphatase enzymes other than desired PAP (data not shown).

The isolated rkbPAP was assayed using *p*-NPP as a substrate. The obtained *K*~m~ and *V*~max~ by fitting data to the Michaelis--Menten equation were 12.6 ± 1.4 and 48 ± 6, respectively. We also designed/synthesized and evaluated the catalytic effects of a number of new inhibitor candidates of rkbPAP, based on the alkylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid scaffold. The inhibitory effects of derivatives **3a**--**d** and **4a**--**d** as well as tartrate as the positive control were tested against rkbPAP at pH 4.9[@CIT0038]. In order to identifying the PAP inhibition mode of test compounds and determining apparent kinetic parameters, the kinetic data were analyzed using [Equation (1)](#M0001){ref-type="disp-formula"}. The IC~50~ and inhibition constant (*K*~i~ and *K*~I~) values of test compounds have been summarized in [Table 1](#t0001){ref-type="table"}. As it was expected, PAP activity was weakly inhibited by tartrate, which is in good agreement with previous reports[@CIT0011]^,^[@CIT0038]. Most of the synthesized compounds demonstrated their inhibitory potentials on PAP in a dose-dependent manner. Among the evaluated compounds, **3d** (IC~50 ~=~ ~92 µM, *K*~i ~= 13 ± 1 µM), **4c** (IC~50 ~=~ ~421 µM, *K*~i ~= 95 ± 9 µM) and **4d** (IC~50 ~=~ ~13 µM, *K*~i ~= 1.1 ± 0.2 µM), were the most potent inhibitors; of which **3d** and **4d** were recognized as potent inhibitors of PAP even stronger than the standard inhibitor[@CIT0011]^,^[@CIT0038]. As can be seen, the *K*~i~ values are in reasonable agreement with the *IC*~50~ values, comparable at least with the best of the naphthalenemethylphosphonic acid derivatives[@CIT0003]^,^[@CIT0018]. Also, the **3a**, **3b**, **4a** and **4b** exhibited negligible inhibitions of PAP, in millimolar range. Thus, these compounds were excluded from further studies (determination of inhibition mode).

###### 

Kinetic data for inhibitors against rkbPAP at pH 4.9.

  Inhibitor name      *IC*~50~ (μM)         *K*~i~ (μM)   *K*~I~ (μM)
  ------------------- --------------------- ------------- -------------
  **3a** and **3b**   Very weak inhibitor   --            --
  **3c**              759                   202 ± 11      211 ± 8
  **3d**              92                    13 ± 1        36 ± 3
  **4a** and **4b**   Very weak inhibitor   --            --
  **4c**              421                   95 ± 9        103 ± 5
  **4d**              13                    1.1 ± 0.2     8.2 ± 1.4
  Tartrate            3315                  783 ± 41      --

Although an in depth SAR analysis is currently impossible, it appears that a major improve in rkbPAP inhibitory activity correlates with increasing the asymmetric hydrophobicity of the compounds. It appears that inhibitor potency increases with increase the length of alkyl chain in alkylsulfonamide moieties ([Table 1](#t0001){ref-type="table"} and [Scheme 1](#SCH0001){ref-type="scheme"}), so that the largest effect on inhibition was achieved with the hexadecyl moiety. Substitution at the dodecyl (in **3c**/**4c**) with hexadecyl (in **3d**/**4d**) greatly decrease the inhibition constant of the inhibitor, suggesting an extremely large hydrophobic or sterically tolerant region near/not into the phosphate binding site of the enzyme as well as a possible preference for the long-chain acyl (≥ C~12~) derivatives. McGeary et al. was reported a similar trend for the rkbPAP and pig PAP enzymes, that is, the longer the alkyl chain the more potent inhibitor of PAPs[@CIT0018].

The inhibition modes of the compounds can be elicited by comparing values of *K*~i~ and *K*~I~ and represented by Lineweaver--Burke plot. Typical Lineweaver--Burk plots for inhibitory activity of **3c** and **4d** as representative have been demonstrated in [Figure 2](#F0002){ref-type="fig"}. If the Lineweaver--Burke plot shows crisscross lines at a single point on the 1/*V* (*y*) axis, it is indicative of competitive inhibition. Also, the trend lines of Lineweaver--Burke plot for **3c** and **4c** compounds intersect each other on the 1/*S* (*x*) axis, which is characteristic of noncompetitive inhibition, so *K*~i ~≈~ ~*K*~I~. Such noncompetitive mode inhibition has also been previously reported for hexyl-derivative of α-alkoxynaphthylmethylphosphonic acid[@CIT0018]. For longer chain-length inhibitors (**3d** and **4d**), the lines of the Lineweaver--Burke plot intersect at a single point between *x-* and *y-*axis, close to the 1/*S* axis, indicate that PAP activity was inhibited with mixed manner by these compounds. On the other hand, since *K*~i ~\<~ ~*K*~I~, the exact mechanism of inhibition is competitive--noncompetitive[@CIT0018]^,^[@CIT0023]^,^[@CIT0026]^,^[@CIT0031]. In agreement with this mode change, McGeary et al. reported that longer alkyl chains of α-alkoxynaphthylmethylphosphonic acid derivatives inhibit rkbPAP and pPAP with mixed (competitive--noncompetitive) manner[@CIT0018]. This behavior may reflect a stronger anchoring effect of the longer alkyl chains into the groove adjacent to the active site of the enzyme, which would favor partially competitive inhibition. Furthermore, the replacement of the diethyl phosphonate group of series **3** by phosphonate in series **4** has a minor decrement effect on the inhibitory effect of compound and does not alter the mode of inhibition, since probably this moiety is not bind/coordinate to bimetal/binuclear center.

![Typical Lineweaver--Burk plots for inhibitory activity of synthetic compounds against rkbPAP. The data represent the average of 3--5 experiments. (A) Lineweaver--Burk plot of rkbPAP activity in the absence (•) and the presence of 300 (\^), 600 (▴) and 1200 μM of **3c** (▵). (B) Lineweaver--Burk plot of rkbPAP activity in the absence (•) and the presence of 10 (\^), 20 (▴) and 40 μM of **4d** (▵).](IENZ_A_1230109_F0002_C){#F0002}

Molecular docking studies {#s0024}
-------------------------

Molecular docking studies on binding modes are essential to elucidate key structural characteristics and interactions and they provide helpful data for designing effective PAP inhibitors[@CIT0041]. Hence, to make the rational design of novel and more selective PAP inhibitors possible, molecular docking was carried out on PAP binding pocket using a set of PAP inhibitors shown in [Scheme 1](#SCH0001){ref-type="scheme"}. As well as RMSD cluster analysis, AutoDock also uses binding free energy assessment to assign the best binding conformation. Energies estimated by AutoDock are described by intermolecular energy (including van der Waals, hydrogen bonding, desolvation, and electrostatic energies), internal energy, and torsional free energy[@CIT0042]. Among these calculated energies by AutoDock, the first two provide the docking energy, while the sum of the first and the third items account for the binding energy. Among all interactions occurring in the active site, the electrostatic interaction between the ligand and the enzyme is the most significant, because in most cases it can assign the strength of binding and the exact position of the inhibitor in the binding site energy[@CIT0042].

The docking results show that all of the studied compounds occupy an almost similar space in the binding site. Also, the calculated binding affinities using computational modeling correlate well with measured inhibition constants (results not shown). Unexpectedly, modeling suggests that the phosphonate moiety of the **3d** inhibitor does not bind to the dimetal center in the active site of rkbPAP. Furthermore, the alkyl chain of the inhibitor binds to the groove on the surface of the enzyme. Other part of molecules including polar atoms and aromatic portions are placed on the hydrophilic patch around the active site, which is in good agreement with the obtained inhibition modes. The best possible binding mode of **3d** as the most biologically active compound in the rkbPAP binding site is illustrated in a three-dimensional ([Figure 3](#F0003){ref-type="fig"}) and two-dimensional space ([Figure 4](#F0004){ref-type="fig"}).

![The three-dimensional representation of docking result of **3d** in the close vicinity of rkbPAP binding pocket (left). Surface and stick representation of the predicted binding mode of **3d** to the enzyme based on docking simulations (right).](IENZ_A_1230109_F0003_C){#F0003}

![The two-dimensional representation of docking result of **3d** compound with binding pocket of rkbPAP.](IENZ_A_1230109_F0004_C){#F0004}

On the other hand, to obtain a detailed description of the effects of individual residues on binding affinity, a per-residue decomposition of the total energy was carried out to evaluate the energetic influences of critical residues on the binding. The residues were separately studied, and the Van der Waals, electrostatic and interaction energies of these residues and **3d** were determined. These include Phe-206, Glu-299, Gly-200, Asp-169, Tyr-256, Ser-287, Met-285 and Leu-289 ([Table 2](#t0002){ref-type="table"}). Energy of interaction between individual residues and ligand was calculated with the "Calculate Interaction Energy" protocol encoded in Discovery Studio. The complexes were typed with CHARMM force field. All parameters used were kept at their default settings. The residue-based decomposition of interaction energies identified several critical residues of PAP. [Table 2](#t0002){ref-type="table"} lists the calculated energies contributions of these key residues of interest. As can be seen, major favorable energy contributions originate predominantly from Phe-206 and Glu-299. The methoxy phenyl core of **3d** is anchored by an aromatic stacking interaction with Phe-206, whereas Glu-299 is one of major contributor of van der Waals interactions.

###### 

Interaction, van der Waals and electrostatic energies for selected residues of PAP and **3d**.

  Residue   Interactionenergy (kcal/mol)   VDW interactionenergy (kcal/mol)   Electrostatic interactionenergy (kcal/mol)
  --------- ------------------------------ ---------------------------------- --------------------------------------------
  PHE206    −12.1                          −3.78                              −8.30
  GLU299    −11.3                          −3.86                              −7.47
  GLY200    −7.45                          −0.18                              −7.27
  ASP169    −7.32                          0.02                               −7.35
  TYR256    −3.67                          −1.66                              −2.01
  SER287    −2.60                          15.2                               −17.8
  MET285    −1.22                          −0.62                              −0.60
  LEU289    −0.27                          −0.27                              0.0

As it can be concluded from [Figures 3, 4](#F0004){ref-type="fig"} and [Table 2](#t0002){ref-type="table"}, the major part of the binding cavity of rkbPAP is hydrophilic, which allows for the tight binding of polar substrates and inhibitors. A long apolar groove adjacent to the active site was identified as an additional potential point of interaction of hydrophobic aliphatic chain and is required for recognition and directionality of the substrate aliphatic chain functionality[@CIT0018]. Also, hydrogens of NH~2~ group of Asn-201 side chain and sulfonamide group of ligand, also hydrogens of NH~2~ group of Phe-206 backbone and oxygen of phosphonate group of ligand form hydrogen bonds (3.12 and 2.90 Å, respectively). It is was interesting to note that the aliphatic chain orients inside the binding cavity and interacts by both hydrophobic as well as hydrophilic interactions ([Table 2](#t0002){ref-type="table"}) with amino acids such as Leu-289 and Met-303. With respect to the docking results ([Figures 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}) Ser-252, Tyr-256, Ser-287, Met-303 and Leu-289 assemble one hydrophobic cluster, which accommodates the aliphatic hydrophobic chain moiety of the ligand. Taking literature[@CIT0026] into account, similar binding orientations of inhibitors in the active sites of pig, red kidney bean and hPAP, may support the contention that the inhibitory potencies obtained using rkbPAP can be extrapolated to hPAP.

Conclusions {#s0025}
===========

To the best of our knowledge, there are no published reports in the literature on the application of alkylsulfonamidophenyl)methyl)phosphonic acid derivatives as potential PAP inhibitors. In the current work, we identified these new derivatives of alkylsulfonamido(4-methoxyphenyl)methyl)phosphonic acid, as potent inhibitors of rkbPAP. The hexadecyl derivative (4d, with *K*~i~ value of 1.1 µM) was found to be the most active compared to compounds contain shorter alkyl chains. In addition, it was illustrated that the inhibitor bound in the vicinity of the enzyme active site showed mixed mode inhibition due to partial competition whit substrate. Considering the crucial role(s) of mammalian PAPs in bone metabolism, such inhibitors are anticipated to be promising lead compounds in the development of new anti-osteoporotic chemotherapeutics.
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